methyl 3-[(6-chloro-1-oxo-4-phenyl-3-propionylisoquinolin-2(1H)-yl)methyl]-1-ethyl-1H-pyrazole-5-carboxylate | 1031352-48-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methyl 3-[(6-chloro-1-oxo-4-phenyl-3-propionylisoquinolin-2(1H)-yl)methyl]-1-ethyl-1H-pyrazole-5-carboxylate
• CAS: 1031352-48-3
• 化学式: C₂₆H₂₄ClN₃O₄
• 分子量: 477.947
• InChiKey: CVXTYVPUZXLKJP-UHFFFAOYSA-N

反应信息

• 作为反应物：
  描述：

  methyl 3-[(6-chloro-1-oxo-4-phenyl-3-propionylisoquinolin-2(1H)-yl)methyl]-1-ethyl-1H-pyrazole-5-carboxylate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 22.0h， 生成 3-[(6-chloro-1-oxo-4-phenyl-3-propanoylisoquinoline-2(1H)-yl)methaneyl]-1-ethyl-1H-pyrazole-5-carboxylic acid
  参考文献：
  名称：

  Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1)

  摘要：

  A novel series of 4-phenylisoquinolones were synthesized and evaluated as c-Jun N-terminal kinase (JNK) inhibitors. Initial modi. cation at the 2- and 3-positions of the isoquinolone ring of hit compound 4, identified from high-throughput screening, led to the lead compound 6b. The optimization was carried out using a JNK1-binding model of 6b and several compounds exhibited potent JNK inhibition. Among them, 11g significantly inhibited cardiac hypertrophy in rat pressure-overload models without affecting blood pressure and the concept of JNK inhibitors as novel therapeutic agents for heart failure was confirmed. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.027
• 作为产物：
  描述：

  methyl 3-((6-chloro-1-oxo-4-phenyl-3-propionyl-2(1H)-isoquinolinyl)methyl)-1H-pyrazole-5-carboxylate 、 碘乙烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以72%的产率得到methyl 3-[(6-chloro-1-oxo-4-phenyl-3-propionylisoquinolin-2(1H)-yl)methyl]-1-ethyl-1H-pyrazole-5-carboxylate
  参考文献：
  名称：

  Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1)

  摘要：

  A novel series of 4-phenylisoquinolones were synthesized and evaluated as c-Jun N-terminal kinase (JNK) inhibitors. Initial modi. cation at the 2- and 3-positions of the isoquinolone ring of hit compound 4, identified from high-throughput screening, led to the lead compound 6b. The optimization was carried out using a JNK1-binding model of 6b and several compounds exhibited potent JNK inhibition. Among them, 11g significantly inhibited cardiac hypertrophy in rat pressure-overload models without affecting blood pressure and the concept of JNK inhibitors as novel therapeutic agents for heart failure was confirmed. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.027